

THE ORIGIN, DIAGNOSIS AND MODERN CLINICAL DIAGNOSIS OF CONGENITAL HEART DEFECTS IN A MODERN INTERPRETATION

¹Mamatov Yusufjon

²Sharipov Shahbozbek

³Razzakova Nozimaxon

^{1,2,3}Samarkand State Medical University, DKTF, Department of Internal Medicine, Cardiology and Functional Diagnostics, 2nd year clinical residents.

<https://doi.org/10.5281/zenodo.14976900>

The urgency of the problem: As a result, the disease is often diagnosed at an advanced stage in these countries, and many people die from CVD and other noncommunicable diseases at a younger age, often in the most productive years of life. At least three-quarters of deaths from cardiovascular disease worldwide occur in low- and middle-income countries. People in these countries often lack access to primary care programs for early detection and treatment of those with cardiovascular risk factors. Patients suffering from cardiovascular disease and other noncommunicable diseases in low- and middle-income countries have less access to effective and equitable health services that meet their needs. At the macroeconomic level, CVDs impose a significant burden on the economies of low- and middle-income countries. The poorest people in low- and middle-income countries are hardest hit. At the individual household level, there is growing evidence that cardiovascular disease and other noncommunicable diseases contribute to household poverty through devastating health care costs and high out-of-pocket costs.

A key measure to reduce CVD rates is to integrate cardiovascular disease interventions into health care packages as part of universal health coverage, although in many countries health systems require significant investment and focus to effectively address CVD.

Essential medications that should be available include: Data from 18 countries show that hypertension control programs can be implemented effectively and cost-effectively at the primary care level, resulting in reduced cardiovascular disease and stroke. Patients with cardiovascular disease need access to appropriate technologies and medications.

Research methods and objects: Cardiovascular diseases (CVD) are a group of diseases of the heart and blood vessels. They include:

peripheral artery disease - a disease of the blood vessels that supply blood to the arms and legs;

coronary heart disease - a disease of the blood vessels that supply blood to the heart muscle;

cerebrovascular disease - a disease of the blood vessels that supply blood to the brain;

rheumatic heart disease - damage to the heart muscle and heart valves as a result of rheumatic fever, which is caused by streptococcal bacteria;

Congenital heart disease - structural deformities of the heart present from birth that affect its normal development and function; and

Deep vein thrombosis and pulmonary embolism - blood clots that form in the veins of the legs and can travel to the heart and lungs.

Heart attacks and strokes are usually acute illnesses that are primarily caused by a blockage in a blood vessel that blocks the flow of blood to the heart or brain. The most common cause is the formation of fatty deposits on the inner walls of the blood vessels that supply blood to the heart or brain. A stroke can occur as a result of bleeding from a blood vessel or the formation of a blood clot.

One important environmental factor is air pollution. Behavioral risk factors can include high blood pressure, high blood glucose or lipids, and being overweight or obese.

The most important behavioral risk factors for heart disease and stroke are poor diet, low physical activity, and harmful use of tobacco and alcohol. These “intermediate risk factors” can be identified in primary care and indicate an increased risk of heart attack, stroke, heart failure, and other complications.

Results: Of the 17 million premature deaths (under the age of 70) from non-communicable diseases in 2019, 38% were attributed to cardiovascular disease. An estimated 17.8 million people died from cardiovascular disease in 2021, accounting for 33% of all deaths worldwide. 75% of these deaths were due to myocardial infarction and stroke.

More than three-quarters of deaths from CVD occur in low- or middle-income countries.

Most cardiovascular diseases can be prevented by addressing behavioral and environmental risk factors such as tobacco use, unhealthy diet and obesity, physical inactivity, harmful alcohol consumption, and air pollution.

It is important to detect cardiovascular disease as early as possible so that help can begin with counseling and medication.

Quitting tobacco use, reducing salt intake, eating fruits and vegetables, being physically active, and avoiding harmful alcohol consumption have been shown to reduce the risk of developing cardiovascular disease. Public health strategies that promote healthy lifestyles and create affordable environments, as well as improving air quality and reducing pollution, are essential for promoting health-promoting behaviors. In addition, there are a number of underlying causes of CVD.

These reflect the main driving forces behind social, economic, and cultural change—globalization, urbanization, and population aging. Other determinants of CVD include poverty, stress, and genetic factors.

Conclusion: The plan aims to reduce premature deaths from NCDs by 25% by 2025 through nine voluntary global targets. Two of these targets are directly aimed at preventing and controlling cardiovascular diseases. Coronary artery disease, Folate metabolism, heart attack, hereditary thrombophilia, Hypertension, Hypertensive heart disease, Individual efficacy of warfarin, Ischemic stroke, Metabolic syndrome, Myocardial infarction, Obesity, hypertension, hypertension, heart disease, myocardial disease, individual efficacy of warfarin, , ischemic stroke, folic acid metabolism, metabolic syndrome, hereditary thrombophilia, obesity.

In 2015, WHO Member States agreed on a global framework for reducing the burden of preventable NCDs, including the Global Action Plan for NCD Prevention and Control 2013–2020.

The study allows us to identify genetic risks for cardiovascular disease, heart attack, stroke, hypertension, thrombophilia, metabolic syndrome, obesity and folic acid cycle disorders, as well as assess individual sensitivity to drugs for the treatment and prevention of cardiovascular diseases.

Based on the results of the study, a genetic specialist's conclusion is issued with recommendations for minimizing existing risks.

REFERENCES

1. Uskov A. et al. Modern methods of therapeutic fasting as a way to overcome the pharmacoresistance of mental pathology //Science and innovation. – 2023. – T. 2. – №. D12. – C. 179-185.
2. Abdukodirova S. SPECIFIC CHARACTERISTICS AND TREATMENT OF ACUTE OBSTRUCTIVE BRONCHITIS IN CHILDREN OF EARLY AGE //Science and innovation. – 2023. – T. 2. – №. D11. – C. 5-8.
3. Tahirova J. et al. Insomnia problem causes of sleep disorder, help measures at home //Science and innovation. – 2022. – T. 1. – №. D8. – C. 521-525.
4. Sultanov S. et al. Long-term salbi effects of the covid-19 pandemic on the health of existing residents of alcohol addiction //Science and innovation. – 2023. – T. 2. – №. D11. – C. 430-438.
5. Madaminov M., . Breast cancer detection methods, symptoms, causes, treatment //Science and innovation. – 2022. – T. 1. – №. D8. – C. 530-535.

6. Шерназаров Самандар, Курбаниязова ВЕ, Виктория Саркисова Владимировна. (2023). Клиническое значение микробиоты кишечника у новорожденных с геморрагической болезнью. IQRO JURNALI, 2 (2), 867-877 [Электронный ресурс].
7. Tahirova J. Symptoms of hymoritis, treatment, methods of folk medicine, prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 983-990.
8. Jalalova D. et al. СОЧЕТАННАЯ СТОМАТОЛОГИЧЕСКАЯ И ГЛАЗНАЯ ПАТОЛОГИЯ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 91-100.
9. Tohirova J. D. Jalalova TYPES OF HEMORRHAGIC DISEASES //CHANGES IN NEWBOENS, THEIR EARLY DIAGNOSIS. - 2022.
10. Tahirova J. et al. Neurose causes and mechanisms of development, symptoms, treatment, prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 515-520.
11. Kiyomov I. IMPROVING SURGICAL TREATMENT METHODS FOR PATIENTS WITH NASAL PATHOLOGY //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 226-231.
12. Sarkisova V. et al. CYTOKINE PROFILE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 336-343.
13. Sarkisova V., Lapasova Z., O. Rakhmanov INFLAMMATORY DISEASES OF THE PELVIC WOMEN ORGANS. – 2023.
14. Jalalova D., Raxmonov X., РОЛЬ С-РЕАКТИВНОГО БЕЛКА В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 114-121.
15. Malakhov A. et al. Modern views on the treatment and rehabilitation of patients with dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 322-329.
16. Jalalova D., Raxmonov X., ЗНАЧЕНИЕ ДИСФУНКЦИИ ЭНДОТЕЛИЯ В РАЗВИТИЕ РЕТИНОПАТИИ У БОЛЬНЫХ АГ И ПУТИ ЕГО КОРРЕКЦИИ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 101-113.
17. Madaminov M. Acute tonsillitis (angina) causes, complications, diagnosis, treatment, prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 771-779.
18. F. The problem of insomnia causes of sleep disorder, remedies at home //Science and innovation. – 2023. – Т. 2. – №. D1. – С. 79-84.

19. Sattarova S., FEATURES OF ELECTROPHYSIOLOGICAL METHODS FOR GUILLAIN–BARRÉ SYNDROME //Science and innovation. – 2023. – T. 2. – №. D10. – C. 199-204.
20. F. Hymoritis symptoms, treatment, methods of folk medicine, prevention //Science and innovation. – 2023. – T. 2. – №. D1. – C. 72-78.
21. Zhalalova D. et al. INFORMATION POINT OF PERIPHERAL BLOOD INDEXES IN THE DIAGNOSIS OF THE ETIOLOGY OF OPTIC NERVE DAMAGE //Science and innovation. – 2023. – T. 2. – №. D11. – C. 124-130.
22. Madaminov M., Causes, symptoms, diagnosis and treatment of kidney stones (urolithiasis). Science and Innovation. 2022; 1.8: 760-765 [Электронный ресурс].
23. Jalalova D., Raxmonov X., ЗНАЧЕНИЕ ДИСФУНКЦИИ ЭНДОТЕЛИЯ В РАЗВИТИЕ РЕТИНОПАТИИ У БОЛЬНЫХ АГ И ПУТИ ЕГО КОРРЕКЦИИ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 101-113.
24. Rotanov, A. (2023). Elderly epilepsy: neurophysiological aspects of non-psychotic mental disorders. Science and innovation, 2(D12), 192-197.
25. Konstantinova, O., (2023). Clinical and psychological characteristics of patients with alcoholism with suicidal behavior. Science and innovation, 2(D11), 399-404.
26. Qizi, T. J. I. (2022). Treatment of myocardial infarction and first aid. Science and innovation, 1(D3), 317-320.
27. Xushvaktova D., Clinical features of mental disorders in synthetic drug users //Science and innovation. – 2023. – Т. 2. – №. D10. – С. 242-247.
28. Solovyova Y. et al. The relevance of psychotic disorders in the acute period of a stroke //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 212-217.
29. Solovyova Y. et al. Suicide prevention in adolescents with mental disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 303-308.
30. Sultanov S. et al. Changes in alcohol behavior during the covid-19 pandemic and beyond //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 302-309.
31. Sultanov S. et al. The impact of the covid-19 pandemic on the mental state of people with alcohol addiction syndrome //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 296-301.
32. Hamidullayevna X. D., Temirpulatovich T. B. Factors of pathomorphosis of alcoholic delirium //Iqro jurnali. – 2023. – Т. 1. – №. 2. – С. 721-729.

33. Sharapova D. et al. Clinical and socio-economic effectiveness of injectable long-term forms of atypical antipsychotics in schizophrenia //Science and innovation. – 2023. – T. 2. – №. D12. – C. 290-295.
34. Sharapova D. Psychological factors for the formation of aggressive behavior in the youth environment //Science and innovation. – 2023. – T. 2. – №. D12. – C. 404-408.
35. Ochilov U. et al. The question of the features of clinical and immunological parameters in the diagnosis of juvenile depression with" subpsychotic" symptoms //Science and innovation. – 2023. – T. 2. – №. D12. – C. 218-222.
36. Sharapova D. Turayev B. Prevalence of mental disorders in children and adolescents with cancer and methods of their treatment //Science and innovation. – 2023. – T. 2. – №. D12. – C. 373-378.